Peter Wijngaard
Keine laufenden Positionen mehr
Vermögen: 1 891 $ am 31.05.2024
Profil
Peter L.
J.
Wijngaard served as Chairman at Aurinia Pharmaceuticals, Inc. and as Director at Ciclofilin Pharmaceuticals, Inc. He was also an Independent Non-Executive Director at Isotechnika Pharma, Inc. and held a Director-Global Alliance position at Hoffmann-La Roche, Inc. Additionally, he was the VP-Innovation Leader Research & Development at The Medicines Company (Schweiz) GmbH.
Wijngaard earned a doctorate degree from the University of Utrecht in 1992.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 20.06.2024 | 1 501 ( 0,03% ) | 1 891 $ | 31.05.2024 |
Ehemalige bekannte Positionen von Peter Wijngaard
| Unternehmen | Position | Ende |
|---|---|---|
| HEPION PHARMACEUTICALS, INC. | Direktor/Vorstandsmitglied | 04.12.2023 |
| The Medicines Company (Schweiz) GmbH | Corporate Officer/Principal | 01.01.2020 |
Ciclofilin Pharmaceuticals, Inc.
 Ciclofilin Pharmaceuticals, Inc. Pharmaceuticals: OtherHealth Technology Ciclofilin Pharmaceuticals, Inc. develops cyclophilin inhibitors for infectious, inflammatory and degenerative diseases. It offers antiviral drug development, liver disease, viral co-infection, cyclophilin inhibition, macrocycle chemistry and protein folding. The company was founded in 2014 by Robert T. Foster and is headquartered in San Diego, PA. | Direktor/Vorstandsmitglied | 01.06.2016 |
Isotechnika Pharma, Inc.
 Isotechnika Pharma, Inc. Pharmaceuticals: MajorHealth Technology Isotechnika Pharma, Inc. is a biopharmaceutical company, which focuses on discovery and development of immunomodulating therapeutics. Its products include voclosporin and non-immunosuppressive cyclosporine analogue molecules. The company was founded by Robert T. Foster founded on June 16, 1993 and is headquartered in Edmonton, Canada. | Direktor/Vorstandsmitglied | 23.10.2013 |
Hoffmann-La Roche, Inc.
 Hoffmann-La Roche, Inc. BiotechnologyHealth Technology Hoffmann-La Roche, Inc. manufactures pharmaceutical drugs. Its products include influenza fighter Tamiflu, controversial acne medication Accutane, HIV inhibitor Fuzeon, obesity drug Xenical, and hepatitis C therapy Pegasys. The company was founded in 1896 Roche and is headquartered in Nutley, NJ. | Direktor/Vorstandsmitglied | - |
Ausbildung von Peter Wijngaard
| University of Utrecht | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| AURINIA PHARMACEUTICALS INC. | Health Technology |
| HEPION PHARMACEUTICALS, INC. | Health Technology |
| Private Unternehmen | 4 |
|---|---|
Isotechnika Pharma, Inc.
Isotechnika Pharma, Inc. Pharmaceuticals: MajorHealth Technology Isotechnika Pharma, Inc. is a biopharmaceutical company, which focuses on discovery and development of immunomodulating therapeutics. Its products include voclosporin and non-immunosuppressive cyclosporine analogue molecules. The company was founded by Robert T. Foster founded on June 16, 1993 and is headquartered in Edmonton, Canada. | Health Technology |
| The Medicines Company (Schweiz) GmbH | |
Ciclofilin Pharmaceuticals, Inc.
Ciclofilin Pharmaceuticals, Inc. Pharmaceuticals: OtherHealth Technology Ciclofilin Pharmaceuticals, Inc. develops cyclophilin inhibitors for infectious, inflammatory and degenerative diseases. It offers antiviral drug development, liver disease, viral co-infection, cyclophilin inhibition, macrocycle chemistry and protein folding. The company was founded in 2014 by Robert T. Foster and is headquartered in San Diego, PA. | Health Technology |
Hoffmann-La Roche, Inc.
Hoffmann-La Roche, Inc. BiotechnologyHealth Technology Hoffmann-La Roche, Inc. manufactures pharmaceutical drugs. Its products include influenza fighter Tamiflu, controversial acne medication Accutane, HIV inhibitor Fuzeon, obesity drug Xenical, and hepatitis C therapy Pegasys. The company was founded in 1896 Roche and is headquartered in Nutley, NJ. | Health Technology |
